DK0477971T3 - Humant CNP gen og precursorprotein - Google Patents

Humant CNP gen og precursorprotein

Info

Publication number
DK0477971T3
DK0477971T3 DK91116557T DK91116557T DK0477971T3 DK 0477971 T3 DK0477971 T3 DK 0477971T3 DK 91116557 T DK91116557 T DK 91116557T DK 91116557 T DK91116557 T DK 91116557T DK 0477971 T3 DK0477971 T3 DK 0477971T3
Authority
DK
Denmark
Prior art keywords
precursor protein
human cnp
human
cnp gene
gene
Prior art date
Application number
DK91116557T
Other languages
Danish (da)
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Shoji Tanaka
Kayoko Fuchimura
Yasunori Tawaragi
Naoto Minamino
Original Assignee
Hisayuki Matsuo
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisayuki Matsuo, Suntory Ltd filed Critical Hisayuki Matsuo
Application granted granted Critical
Publication of DK0477971T3 publication Critical patent/DK0477971T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91116557T 1990-09-27 1991-09-27 Humant CNP gen og precursorprotein DK0477971T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトｃｎｐ遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
DK0477971T3 true DK0477971T3 (da) 1998-09-21

Family

ID=17337688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91116557T DK0477971T3 (da) 1990-09-27 1991-09-27 Humant CNP gen og precursorprotein

Country Status (8)

Country Link
US (1) US6034231A (es)
EP (2) EP0769554B1 (es)
JP (1) JP3026354B2 (es)
AT (2) ATE162532T1 (es)
DE (2) DE69128754T2 (es)
DK (1) DK0477971T3 (es)
ES (2) ES2113865T3 (es)
GR (1) GR3026554T3 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
CN1960757A (zh) 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2007061715A2 (en) * 2005-11-18 2007-05-31 The Brigham & Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective vascular endothelium
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
CN101809029B (zh) * 2008-05-23 2016-06-15 第一三共株式会社 具有延长目标肽的血浆半衰期作用的肽
ES2608457T3 (es) 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
KR20260046164A (ko) 2015-07-30 2026-04-06 바이오마린 파머수티컬 인크. 골 이형성증 치료를 위한 c―형 나트륨이뇨 펩타이드 변이체의 용도
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20240160671A (ko) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
BR112022004697A2 (pt) 2019-09-16 2022-06-14 Biomarin Pharm Inc Variantes de cnp e conjugados das mesmas
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3226388A1 (en) 2021-07-09 2023-01-12 Biomarin Pharmaceutical Inc. C-type natriuretic peptide variants to treat skeletal dysplasia in children
AU2022407450A1 (en) 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
EP4612167A1 (en) 2022-11-02 2025-09-10 Novo Nordisk A/S Cnp compounds
WO2024254405A2 (en) 2023-06-07 2024-12-12 Biomarin Pharmaceutical Inc. High throughput screen for genetic variants associated with short stature
TW202535449A (zh) 2023-11-08 2025-09-16 美商拜奧馬林製藥公司 Ｃｎｐ變異體、其接合物及調配物
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
EP0769554B1 (en) 2008-03-05
ES2302333T3 (es) 2008-07-01
EP0477971B1 (en) 1998-01-21
ATE388165T1 (de) 2008-03-15
JPH04139199A (ja) 1992-05-13
GR3026554T3 (en) 1998-07-31
DE69133593T2 (de) 2009-04-02
ES2113865T3 (es) 1998-05-16
JP3026354B2 (ja) 2000-03-27
DE69133593D1 (de) 2008-04-17
ATE162532T1 (de) 1998-02-15
EP0477971A3 (en) 1992-09-09
DE69128754T2 (de) 1998-06-04
EP0769554A3 (en) 1997-05-28
US6034231A (en) 2000-03-07
EP0477971A2 (en) 1992-04-01
EP0769554A2 (en) 1997-04-23
DE69128754D1 (de) 1998-02-26

Similar Documents

Publication Publication Date Title
DK0477971T3 (da) Humant CNP gen og precursorprotein
IL131016A0 (en) Selection of proteins using rna-protein fusions
ES2153037T3 (es) Lacasas purificadas de scytalidium y acidos nucleicos que las codifican.
PT88425A (pt) Dna sequences recombinant dna molecules and processes for producing soluble t4 proteins
DE3884529D1 (de) Leader-anteile zur produktion von rekombinanten proteinen.
DK1490386T3 (da) Nyt polypeptid og nukleinsyrer kodende for dette
DE3672924D1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ES2184728T3 (es) Proteinas de union a la fibronectina.
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
FI900075L (fi) Medvaexthormon bindande peptid.
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
DE69534738D1 (de) Leukocyten-aktivierender Faktor
FI944997A7 (fi) Parannettu rekombinantti-proteiinien tuotanto
DK130290A (da) Lymfokiner, dna-sekvenser, som koder for disse lymfokiner og farmaceutiske midler indeholdende disse lymfokiner
DE69127743D1 (de) Für ein Protein, das sich mit dem Enhancer des Alpha-Fetoprotein verbindet, kodierende DNS
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
IE882662L (en) Dna sequences, recombinant dna molecules for producing¹soluble t4 proteins
ZA886593B (en) Dna sequences,recombinant dna molecules and processes for producing soluble t4 proteins